Pill that costs just pennies a day linked to decreased risk of dementia, study suggests
Long before Ozempic splashed onto the scene, transforming type 2 diabetes treatment, there was metformin.
Used for about 100 years, metformin lowers the amount of sugar the liver pumps out and helps the body respond to insulin better. It has been the first-line treatment for more than 70 percent of people newly diagnosed with type 2 diabetes.
Doctors have suggested through observational studies for several years that the mainstay of diabetes, which roughly 19 million people take for $2 to $20 per month, could have preventive power.
Still, evidence has been mixed, with some studies suggesting the drug exacerbates the development of Alzheimer's disease, just one type of dementia, and several others saying it has a protective effect on the brain.
Now, doctors from Taipei Medical University in Taiwan are the latest to make the case for the latter.
They found that, in half a million overweight and obese people without diabetes, those who took metformin had a lower risk of developing dementia or dying from any cause, regardless of their BMI.
Similar to type 2 diabetes, obesity is a risk factor for dementia. Being severely overweight lowers the body's defenses against the damage dementia inflicts on the brain and causes chronic inflammation, potentially damaging nerve cells.
Until now, research into metformin as a dementia preventative has primarily focused on people with diabetes. The latest report from Taiwanese researchers is the first to use real-world data to investigate the possibility in people with obesity.
The scientists noted the real-world data reflects a diverse population, making the study's findings widely applicable.
They used an electronic health records database covering millions of patients from 66 US healthcare systems, including hospitals, specialty centers, and clinics.
The researchers said: 'Since central nervous system inflammation and neuroinflammation are crucial factors in the development and progression of neurodegenerative diseases, the anti-inflammatory and antioxidative effects of metformin are especially beneficial in patients with obesity.
'Regular, long-term use of metformin may be an efficient way to prevent dementia.'
The study included about 905,000 people in total, split evenly into two groups: those on and those not on metformin. They were matched to be similar in age, health, and other factors for a fair comparison.
The metformin group had been prescribed the drug at least twice in their lives for at least six months.
The study did not explicitly state why people had been prescribed the drug, but it can be used to treat more than just diabetes, such as prediabetes, those with a metabolic disorder that contributes to obesity, and for polycystic ovary syndrome.
Researchers categorized their study subjects, all adults over 18, into four groups: overweight (BMI 25–29.9), Obese class I (BMI 30–34.9), Obese class II (BMI 35–39.9) and morbidly obese (BMI over 40).
After following patients for 10 years, those who took metformin had a lower risk of developing dementia across all BMI groups.
The amount of risk reduction varied slightly depending on weight, but two of the groups saw significant results.
People with a BMI of 30 to 34.9 had a dementia risk about eight percent lower than non-users, while those with a BMI between 25 and 29.9 had a risk about 12.5 percent lower.
People with a BMI of 35 to 39.9 had a four percent lower risk, which researchers deemed statistically insignificant, potentially due to a smaller sample size.
There was no significant difference in people with a BMI over 40.
When looking at death from any cause, metformin users also had a significantly lower risk across all BMI categories.
Metformin's effect on death risk was stronger than its effect on dementia risk. Those with a BMI between 25 and 29.9 had a 28 percent lower risk of death, while those with a BMI of 30 to 34.9 had a 27 percent lower risk.
People with a BMI of 35 to 39.9 had a 28 percent lower risk of death, and people with a BMI of 40 or above saw a 26 percent lower risk.
The Taipei team's findings were published in the journal Diabetes, Obesity and Metabolism.
Scientists attribute metformin's recently explored impact on cognitive health and dementia to factors unique to the drug and the condition it treats.
A type 2 diabetes diagnosis is a leading risk factor for dementia, with one sweeping review in 2013 finding that diabetes patients have a 73 percent higher likelihood of developing dementia and a 56 percent higher likelihood of developing Alzheimer's.
Both conditions affect millions in the US. Around 35 million Americans have type 2 diabetes, while an estimated 7million have dementia, including roughly four to 6 million with Alzheimer's disease.
Several studies have resulted in compelling evidence that supports metformin's anti-dementia abilities.
In 2020, Australian researchers followed over 1,000 dementia-free seniors aged 70 to 90 from Sydney for up to six years, testing their memory and thinking skills at two and six years.
The study looked at three main groups: people with type 2 diabetes who were taking metformin, those with diabetes who were not, and people without diabetes.
The participants in the study, who did not have dementia at the start, were tested at two years and again at six years for their in-depth memory and executive functioning.
After accounting for other health factors, researchers found that the metformin group had an 81 percent lower risk of dementia compared to those with diabetes who weren't on metformin.
People with diabetes who didn't take metformin were nearly three times more likely to develop dementia than people without diabetes.
Brain scans and thinking tests also suggested that metformin users experienced a slower decline in cognitive abilities, particularly in decision-making and overall brain function.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
7 minutes ago
- The Independent
Breakthrough study finds Alzheimer's could be due to this deficiency
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added.
BBC News
2 hours ago
- BBC News
Get your groove on! Cockatoos have 30 distinct dance moves
You might have seen videos of cockatoos dancing with their owners on social media, but did you know they can perform up to 30 distinct dance moves? Head banging and body rolls are just some of the new moves scientists from Charles Sturt University in Australia have observed in the birds. They identified 17 new dance moves which can be performed with or without music, and the 30 dance moves can be combined into unique dancing in time to music has only been reported in humans and parrots - like cockatoos - but scientists still aren't sure why they dance in captivity. Some wild birds display rhythmic movements as part of courtship displays to try and find a mate. Dancing requires a lot of complicated brain processes including imitation, learning and moving in time to music. Several species of parrot have been observed dancing to music in captivity and researchers analysed 45 social media videos showing cockatoos dancing as part of the study. The 17 new moves haven't been described scientifically before, including body rolls, side-stepping and researchers found that some birds also performed their own individual dance moves and each species had its own most common moves. The researchers also looked at dancing behaviour in six cockatoos from three species at Wagga Wagga Zoo in Australia. They found that whether they were playing music or not, all birds performed dance moves. The study shows it's more common in cockatoos than previously least 10 out of the 21 species of cockatoo can throw shapes and many have a wide range of dance moves. The scientists think their abilities may have come from their courtship behaviour and they argue it shows how intelligent the birds really are. They added that dance behaviour can be a good indicator of birds' emotions and that playing music to parrots could help to enrich their lives.
The Independent
4 hours ago
- The Independent
Shroud of Turin imprint might not be from human body, study says
The imprint of a human-like figure on the Shroud of Turin may have come from a shallow sculpture and not an actual person, according to a new study that sheds more light on the world's most studied archaeological artefact. The shroud measuring 14ft by 3.6ft first emerged in the 1350s, bearing the faint image of a man that many believe to be the imprint of Jesus Christ. It displays the frontal and dorsal figures of an adult man with signs of physical violence. Researchers have long debated the origin of the linen cloth, with some dating it to around the time of Jesus Christ's crucifixion and others deeming it a medieval forgery. Now, a study by a Brazilian designer claims the shroud is most likely 'a medieval work of art'. Cicero Morares is known for using 3D digital modelling to analyse how different types of cloth drape over various shapes or figures and to map their respective contact areas. The study, published in the journal Archaeometry, employs an open-source software to assess how fabric forms impressions from a full three-dimensional human body as compared to a low-relief sculpture formed by raising a figure slightly from a flat background. 'Two scenarios were compared,' the study says, 'the projection of a three-dimensional human model and that of a low-relief model.' The low-relief figure produced an imprint on the fabric similar to that on the Turin shroud. 'The results demonstrate that the contact pattern generated by the low-relief model is more compatible with the Shroud's image,' it concludes. Morares says the scenario of fabric contouring a low-relief sculpture shows greater similarity to the observed contours on the shroud while the projection of a 3D human body results in a 'significantly distorted image'. The designer suspects such a sculpture may have been made of wood, stone or metal and likely pigmented only in the areas of contact to produce the kind of pattern seen on the shroud. 'The accessible and replicable methodology suggests that the shroud's image is more consistent with an artistic low-relief representation than with the direct imprint of a real human body,' the study says. The findings, according to the Brazilian researcher, supports a hypothesis of the shroud's origin 'as a medieval work of art'.
